NDLI: Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects

Please wait, while we are loading the content...

Metallomics Vol -9

Metallomics Vol -8

Metallomics Vol - 1 Issue - 6

Metallomics Vol - 1 Issue - 5

Metallomics Vol - 1 Issue - 4

Metallomics Vol - 1 Issue - 3

Front cover

Inside front cover

Contents and Chemical Biology

Metallomics scope ( Metallomics Vol - 1 Issue - 3 )

Changing the face of scientific publishing

Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects

Zinc and tetrathiomolybdate for the treatment of Wilson’s disease and the potential efficacy of anticopper therapy in a wide variety of diseases

Interplay of metal ions and urease

Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium

Independent metal-binding features of recombinant metallothioneins convergently draw a step gradation between Zn- and Cu-thioneins

Characterization of metal–peptide complexes in feed supplements of essential trace elements

Hijacking transferrin bound iron: protein–receptor interactions involved in iron transport in N. gonorrhoeae

Unusual flexibility of distal and proximal histidine residues in the haem pocket of Drosophila melanogaster haemoglobin

Back matter

Back cover

Metallomics Vol - 1 Issue - 2

Metallomics Vol - 1 Issue - 1

Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects

Content Provider	Royal Society of Chemistry (RSC)
Author	Timerbaev, Andrei R.
Copyright Year	2009
Abstract	Gallium-based anticancer chemotherapeutics are appreciably progressing in clinical studies. A steady interest of drug developers and clinicians in gallium compounds is due to a proven ability of gallium cations to inhibit tumour growth, on the one hand, and enhanced bioavailability and moderate toxicity provided by the conversion of gallium into chelate complexes, on the other. One of the complexes suitable for a more convenient oral administration is tris(8-quinolinolato)gallium(III) (KP46). Nominated from a range of gallium complexes for the clinical stage of development, KP46 has finished phase I trials with the outcome of promising tolerability and evidence of clinical activity in renal cell carcinoma. Therefore, there is obviously a need to codify and critically evaluate the continuing advances in the emergence of KP46 as a lead-drug candidate. Additionally, many questions remain unanswered regarding the relevant biological reactivity, modes of delivery and action and potential cell target(s) of KP46. The timely publication of the present review is also an attempt to shed light on these pertinent drug assets and to accelerate research activities towards further clinical development of KP46.
Starting Page	193
Ending Page	198
Page Count	6
File Format	HTM / HTML PDF
ISSN	17565901
Volume Number	1
Issue Number	3
Journal	Metallomics
DOI	10.1039/b902861g
Language	English
Publisher	Royal Society of Chemistry
Access Restriction	Open
Subject Keyword	Gallium Carcinoma Bioavailability
Content Type	Text
Resource Type	Article
Subject	Chemistry Medicine Metals and Alloys Biochemistry Biomaterials Biophysics

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Tris(2-methyl-8-quinolinolato)gallium(III) as a Fluorescent Probe for Sensitive Silanol-Testing

Gold(iii) bis(dithiolene) complexes: from molecular conductors to prospective anticancer, antimicrobial and antiplasmodial agents

Gallium phosphinoarylbisthiolato complexes counteract drug resistance of cancer cells

The structure of the methanol adduct of tris-(8-quinolinolato)-chromium(III)

Cyclometallated Au(III) dithiocarbamate complexes: synthesis, anticancer evaluation and mechanistic studies

An insight into silver nanoparticles bioavailability in rats

Silanol Effect on the Chromatographic Behavior of Tris(2-methyl-8-quinolinolato)gallium in High-Performance Liquid Chromatography

Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research

First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro†

Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects

Similar Documents

Tris(2-methyl-8-quinolinolato)gallium(III) as a Fluorescent Probe for Sensitive Silanol-Testing

Gold(iii) bis(dithiolene) complexes: from molecular conductors to prospective anticancer, antimicrobial and antiplasmodial agents

Gallium phosphinoarylbisthiolato complexes counteract drug resistance of cancer cells

The structure of the methanol adduct of tris-(8-quinolinolato)-chromium(III)

Cyclometallated Au(III) dithiocarbamate complexes: synthesis, anticancer evaluation and mechanistic studies

An insight into silver nanoparticles bioavailability in rats

Silanol Effect on the Chromatographic Behavior of Tris(2-methyl-8-quinolinolato)gallium in High-Performance Liquid Chromatography

Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research

First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro†

Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects